Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ImmuPharma ( (GB:IMM) ) has shared an announcement.
ImmuPharma PLC has announced the appointment of Crowe LLP as its new auditor, replacing CLA Evelyn Partners Limited. This change is effective immediately and Crowe will audit the company’s financial statements for the year ending December 31, 2024. A proposal for Crowe’s reappointment will be presented at the 2025 Annual General Meeting, highlighting a strategic shift in the company’s financial operations. This move could impact the company’s industry positioning by potentially enhancing financial oversight and transparency to its stakeholders.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focusing on the discovery and development of peptide-based therapeutics. It has a portfolio that includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The company’s lead program, P140, is aimed at treating Systemic Lupus Erythematosus and Chronic Idiopathic Demyelinating Polyneuropathy, with potential activity for other autoimmune diseases.
YTD Price Performance: -28.31%
Average Trading Volume: 1,423,547
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £4.98M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.